ADPT

SEC source: 0001780660-25-000002 · primary_doc.xml · derivative · entry 7

LO FRANCIS · CIK 0001780660 · Chief People Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 109,176

Underlying: Common Stock · 19,423 shares

Expires 2033-03-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.

F4 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

SEC source: 0001780660-25-000002 · primary_doc.xml · derivative · entry 6

LO FRANCIS · CIK 0001780660 · Chief People Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 113,250

Underlying: Common Stock · 37,750 shares

Expires 2029-05-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.

F3 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001780660-25-000002 · primary_doc.xml · nonDerivative · entry 4

LO FRANCIS · CIK 0001780660 · Chief People Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 315,978

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.

F2 · price: The price reported for this transaction is a weighted -average price. The shares were sold in multiple transactions ranging from $15.37 to $16.03, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001780660-25-000002 · primary_doc.xml · nonDerivative · entry 3

LO FRANCIS · CIK 0001780660 · Chief People Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 429,868

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.

SEC source: 0001780660-25-000002 · primary_doc.xml · nonDerivative · entry 2

LO FRANCIS · CIK 0001780660 · Chief People Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 390,019

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.

SEC source: 0001780660-25-000002 · primary_doc.xml · nonDerivative · entry 1

LO FRANCIS · CIK 0001780660 · Chief People Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 370,596

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.

SEC source: 0001274139-25-000003 · primary_doc.xml · nonDerivative · entry 1

HERSHBERG ROBERT · CIK 0001274139 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 46,722

SEC source: 0001780851-25-000003 · primary_doc.xml · nonDerivative · entry 2

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,232,312

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading plan adopted by the reporting person on August 11, 2025.

F3 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.45 to $16.95, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001780854-25-000003 · primary_doc.xml · derivative · entry 7

BENZENO SHARON · CIK 0001780854 · Chief Commercial Ofc Imm Med

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 112,247

Underlying: Common Stock · 4,157 shares

Expires 2034-03-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2025.

F5 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 4, 2025, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

SEC source: 0001780854-25-000003 · primary_doc.xml · derivative · entry 6

BENZENO SHARON · CIK 0001780854 · Chief Commercial Ofc Imm Med

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 62,360

Underlying: Common Stock · 4,157 shares

Expires 2033-03-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2025.

F4 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

SEC source: 0001780854-25-000003 · primary_doc.xml · derivative · entry 5

BENZENO SHARON · CIK 0001780854 · Chief Commercial Ofc Imm Med

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 12,871

Underlying: Common Stock · 4,290 shares

Expires 2032-03-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2025.

F3 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 4, 2023, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

SEC source: 0001780854-25-000003 · primary_doc.xml · nonDerivative · entry 4

BENZENO SHARON · CIK 0001780854 · Chief Commercial Ofc Imm Med

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 296,791

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2025.

F2 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.66 to $16.93, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001780854-25-000003 · primary_doc.xml · nonDerivative · entry 3

BENZENO SHARON · CIK 0001780854 · Chief Commercial Ofc Imm Med

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 309,395

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2025.

SEC source: 0001780854-25-000003 · primary_doc.xml · nonDerivative · entry 2

BENZENO SHARON · CIK 0001780854 · Chief Commercial Ofc Imm Med

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 305,238

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2025.

SEC source: 0001780854-25-000003 · primary_doc.xml · nonDerivative · entry 1

BENZENO SHARON · CIK 0001780854 · Chief Commercial Ofc Imm Med

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 301,081

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2025.

SEC source: 0001780851-25-000003 · primary_doc.xml · nonDerivative · entry 1

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,242,312

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading plan adopted by the reporting person on August 11, 2025.

F2 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.50 to $18.71, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001780649-25-000003 · primary_doc.xml · nonDerivative · entry 2

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,709,241

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2025.

F3 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.78 to $19.20, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001780662-25-000003 · primary_doc.xml · derivative · entry 7

PISKEL KYLE · CIK 0001780662 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 8,581

Underlying: Common Stock · 94,384 shares

Expires 2032-03-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 28, 2025.

F4 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 4, 2023, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

SEC source: 0001780662-25-000003 · primary_doc.xml · derivative · entry 6

PISKEL KYLE · CIK 0001780662 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,750 shares

Expires 2029-04-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 28, 2025.

F3 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001780662-25-000003 · primary_doc.xml · derivative · entry 5

PISKEL KYLE · CIK 0001780662 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 11,980 shares

Expires 2028-10-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 28, 2025.

F3 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001780662-25-000003 · primary_doc.xml · nonDerivative · entry 4

PISKEL KYLE · CIK 0001780662 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 216,637

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 28, 2025.

F2 · price: The price reported for this transaction is a weighted -average price. The shares were sold in multiple transactions ranging from $19.28 to $19.72, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001780662-25-000003 · primary_doc.xml · nonDerivative · entry 3

PISKEL KYLE · CIK 0001780662 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 379,457

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 28, 2025.

SEC source: 0001780662-25-000003 · primary_doc.xml · nonDerivative · entry 2

PISKEL KYLE · CIK 0001780662 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 285,073

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 28, 2025.

SEC source: 0001780662-25-000003 · primary_doc.xml · nonDerivative · entry 1

PISKEL KYLE · CIK 0001780662 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 281,323

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 28, 2025.

SEC source: 0001780649-25-000003 · primary_doc.xml · nonDerivative · entry 1

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,834,239

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2025.

F2 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.43 to $20.29, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001780854-25-000002 · primary_doc.xml · derivative · entry 18

BENZENO SHARON · CIK 0001780854 · Chief Commercial Ofc Imm Med

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 116,404

Underlying: Common Stock · 83,145 shares

Expires 2034-03-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2025.

F8 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 4, 2025, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

SEC source: 0001780854-25-000002 · primary_doc.xml · derivative · entry 17

BENZENO SHARON · CIK 0001780854 · Chief Commercial Ofc Imm Med

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 17,161

Underlying: Common Stock · 119,809 shares

Expires 2032-03-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2025.

F3 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 4, 2023, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

SEC source: 0001780854-25-000002 · primary_doc.xml · derivative · entry 16

BENZENO SHARON · CIK 0001780854 · Chief Commercial Ofc Imm Med

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 34,375 shares

Expires 2029-02-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2025.

F7 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on January 1, 2020, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

SEC source: 0001780854-25-000002 · primary_doc.xml · derivative · entry 15

BENZENO SHARON · CIK 0001780854 · Chief Commercial Ofc Imm Med

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 49,480 shares

Expires 2028-10-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2025.

F6 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on October 1, 2019, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

SEC source: 0001780854-25-000002 · primary_doc.xml · derivative · entry 14

BENZENO SHARON · CIK 0001780854 · Chief Commercial Ofc Imm Med

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 20,834 shares

Expires 2028-02-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2025.

F5 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on November 1, 2018, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

SEC source: 0001780854-25-000002 · primary_doc.xml · derivative · entry 13

BENZENO SHARON · CIK 0001780854 · Chief Commercial Ofc Imm Med

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 834 shares

Expires 2027-04-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2025.

F4 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on April 19, 2018, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

SEC source: 0001780854-25-000002 · primary_doc.xml · nonDerivative · entry 10

BENZENO SHARON · CIK 0001780854 · Chief Commercial Ofc Imm Med

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 296,791

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2025.

F10 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.50 to $17.44, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001780854-25-000002 · primary_doc.xml · nonDerivative · entry 9

BENZENO SHARON · CIK 0001780854 · Chief Commercial Ofc Imm Med

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 605,268

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2025.

SEC source: 0001780854-25-000002 · primary_doc.xml · nonDerivative · entry 8

BENZENO SHARON · CIK 0001780854 · Chief Commercial Ofc Imm Med

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 522,123

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2025.

SEC source: 0001780854-25-000002 · primary_doc.xml · nonDerivative · entry 7

BENZENO SHARON · CIK 0001780854 · Chief Commercial Ofc Imm Med

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 402,314

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2025.

SEC source: 0001780854-25-000002 · primary_doc.xml · nonDerivative · entry 6

BENZENO SHARON · CIK 0001780854 · Chief Commercial Ofc Imm Med

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 367,939

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2025.

SEC source: 0001780854-25-000002 · primary_doc.xml · nonDerivative · entry 5

BENZENO SHARON · CIK 0001780854 · Chief Commercial Ofc Imm Med

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 318,459

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2025.

SEC source: 0001780854-25-000002 · primary_doc.xml · nonDerivative · entry 4

BENZENO SHARON · CIK 0001780854 · Chief Commercial Ofc Imm Med

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 297,625

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2025.

SEC source: 0001780854-25-000002 · primary_doc.xml · derivative · entry 12

BENZENO SHARON · CIK 0001780854 · Chief Commercial Ofc Imm Med

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 136,970

Underlying: Common Stock · 68,961 shares

Expires 2032-03-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2025.

F3 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 4, 2023, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

SEC source: 0001780854-25-000002 · primary_doc.xml · derivative · entry 11

BENZENO SHARON · CIK 0001780854 · Chief Commercial Ofc Imm Med

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 66,517

Underlying: Common Stock · 133,032 shares

Expires 2033-03-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2025.

F2 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 6, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

SEC source: 0001780854-25-000002 · primary_doc.xml · nonDerivative · entry 3

BENZENO SHARON · CIK 0001780854 · Chief Commercial Ofc Imm Med

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 296,791

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2025.

F9 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.50 to $16.90, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001780854-25-000002 · primary_doc.xml · nonDerivative · entry 2

BENZENO SHARON · CIK 0001780854 · Chief Commercial Ofc Imm Med

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 594,716

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2025.

SEC source: 0001780854-25-000002 · primary_doc.xml · nonDerivative · entry 1

BENZENO SHARON · CIK 0001780854 · Chief Commercial Ofc Imm Med

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 525,755

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2025.

SEC source: 0001780662-25-000002 · primary_doc.xml · nonDerivative · entry 1

PISKEL KYLE · CIK 0001780662 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 269,343

F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

SEC source: 0001780649-25-000002 · primary_doc.xml · nonDerivative · entry 3

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,869,975

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2025.

F4 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.03, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001780649-25-000002 · primary_doc.xml · nonDerivative · entry 2

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,871,851

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2025.

F3 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.52 to $14.66, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001780649-25-000002 · primary_doc.xml · nonDerivative · entry 1

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,873,088

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2025.

F2 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.37 to $15.05, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001780851-25-000002 · primary_doc.xml · nonDerivative · entry 1

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,269,524

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2025.

F2 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.58 to $15.05, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001062993-25-009837 · form4.xml · nonDerivative · entry 2

PISKEL KYLE · CIK 0001780662 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 277,396

F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

SEC source: 0001062993-25-009904 · form4a.xml · nonDerivative · entry 1

PISKEL KYLE · CIK 0001780662 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 269,581

F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.